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Abstract
Background: Propionic acid is a three-carbon short chain fatty acid (SCFA) that has various effects on colonic
functions. Although several studies have shown the effects of propionic acid on intestinal mucosal barrier function,
studies of the promotion effect during pre-weaning are rare in the literature as far as we know.
Methods: Pre-weaning male Sprague-Dawley rats 7 days after birth were given an oral 0.2 mL/10 g of 200 mM
propionic acid solution in the propionic acid group or normal saline solution in the control group by gavage twice
a day for ten days. The proximal colonic contents were used for extraction and determination of propionic acid by
gas chromatographic analysis; the transepithelial electrical resistance (TER) of colonic tissue was detected by an
Ussing chamber; the alterations of ZO-1, Claudin-1, Claudin-8 and Occludin proteins were analyzed by Western blot
and immunohistochemistry; and The activity of ERK and p38 MAPK was determined by the phosphorylation status
of ERK1/2 and p38 with Western blot.
Results: Our results suggested a higher concentration (23.5 ± 1.9 mmol/kg) of propionic acid compared to the
physiological concentration (18.1 ± 0.9 mmol/kg) in colonic contents after oral administration increased the value of
TER and the expression of ZO-1, Claudin-1, Claudin-8 and Occludin compared to the control group. Furthermore,
the expression levels of phosphorylated ERK1/2 and p38 MAPK were increased in propionic acid group.
Conclusions: We concluded that continuous oral administration of propionic acid during lactation may increase its
concentration in the proximal colon and promote epithelial barrier function of proximal colon by enhancing the
expression of ZO-1, Claudin-8, Claudin-1 and Occludin via increases in the expression of ERK1/2 and p38 MAPK.
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Background
Short chain fatty acids (SCFAs), primarily acetic acid,
propionic acid and butyric acid, are mainly produced by
the fermentation of fibers and resistant starches that re-
quire the presence of specific colonic bacteria [1]. There
is now an abundance of evidence to indicate that SCFAs
play an important role in the maintenance of health and
the development of disease [2, 3]. It has been confirmed
that SCFAs can not only serve as the principal energy
source for colonic epithelia, but they can also reduce the
incidence of colonic inflammatory disease by inhibiting
inflammatory cytokine release [4, 5]. In particular,
SCFAs are considered to play an important role in anti-
tumorigenic activity by inhibiting cancer cell prolifera-
tion and inducing apoptosis [6, 7].
The barrier function of colonic mucosa plays a key
role in maintaining the balance between host and intes-
tinal microbes. Tight junctions (TJs) as the critical phys-
ical intestinal barrier are the principal determinant of
mucosal permeability [8]. Occludin, claudins and junc-
tional adhesion molecules are the major transmembrane
proteins linked to the cytoskeleton by zonula occludens
(ZO), and they constitute the TJ [9]. The intestinal TJ
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seals the space between adjacent epithelia to effectively
prevent pathogenic bacteria, endotoxins and other
harmful substances from crossing the mucosa to the
blood and the abdominal cavity [10].
SCFAs can dose-dependently suppress the permeabil-
ity of isolated colonic mucosa and the Caco-2 cell
monolayer in the short term in vitro [11, 12]. However,
most of the literature focuses on butyrate and to a lesser
extent on acetate. Consequently, the potential effects of
propionic acid have long been underestimated [13]. In
addition, pre-weaning is a special period in which the in-
testinal mucosal barrier has not yet matured, which re-
sults in the lack of resistance to various stresses [14].
Therefore, the pre-weaning rats were given an oral
2 mL/10 g of 200 mM propionic acid solution by gavage,
and our study demonstrated that the oral administration
of propionic acid during lactation increased its concen-




Phosphate-buffered saline (PBS) was purchased from
Solarbio (Life Sciences Co. Ltd, Beijing, China). acetic
acid, propionic acid and butyric acid, ethyl acetate, D-
Mannitol, D-(+)-Glucose and agarose were purchased
from Sigma (St Louis, MO, USA). Polyclonal rabbit anti-
bodies for ZO-1, Claudin-8, Claudin-1 (Invitrogen Inc.,
USA), Occludin (Proteintech, Hubei, China), p38
MAPK, phospho-p38 MAPK, ERK1/2, phospho-ERK1/2
(Cell Signaling Technology, USA) and the monoclonal
mouse antibody for glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) (Bioworld Inc., USA) were used
as the primary antibodies. Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG antibodies and
HRP-conjugated goat anti-mouse IgG antibodies (Bio-
world Inc., USA) were used as secondary antibodies.
The DAB Detection Kit (Polymer) (ZSGB-BIO, Beijing,
China) was used for immunohistochemistry. SuperSignal
West Dura Extended Duration Substrate (ThermoFisher,
USA) was applied for chemiluminescence.
Animals
All of the experimental procedures were performed in
compliance with the ethical principles of animal welfare.
Pre-weaning male Sprague-Dawley rats (Laboratory
Animal Centre, Wenzhou Medical University, China)
7 days after birth (18–20 g) were randomized into the
control and propionic acid groups. The rats were given
an oral 0.2 mL/10 g of 200 mM propionic acid solution
in the propionic acid group or a normal saline solution
in the control group by gavage twice a day for ten days.
On the 11th experimental day, all of the rats were
anesthetized and sacrificed to collect tissue and the con-
tents of the colon.
Gas chromatographic analysis
Each gram of colon contents was thawed and suspended
in 5 mL of water and homogenized with a vortex for
2 min, followed by centrifugation (>10,000 r/min) for
10 min. Next, 0.1 mL of 0.5 M sulfuric acid was added
to the supernatant of the colon content solution per
milliliter to adjust the pH. Each milliliter of supernatant
was extracted with 1 mL of ethyl acetate by vortex mix-
ing for 2 min, centrifuged (>10,000 r/min) for 10 min
and then incubated at 4 °C for 30 min. The supernatant
ethyl acetate extracts were stored at −20 °C before gas
chromatography (GC) analysis.
Chromatographic analysis was performed using an
Agilent 6890 N GC system equipped with a flame
ionization detector (FID) and an N10149 automatic li-
quid sampler [15], an HP-INNOWAX column, 30 m ×
0.32 mm × 0.25 μm (Agilent, USA), was also used.
The temperature increase procedure was performed as
follows: the initial temperature was 100 °C and was main-
tained for 0.5 min, then increased to 180 °C at 8 °C/min
and maintained for 1 min, then increased to 200 °C
at 20 °C/min, and finally maintained at 200 °C for
5 min. The temperatures of the injection port and
FID detector were 200 °C and 240 °C, respectively.
The flow rate of nitrogen was 20 mL/min with a split
ratio of 1:10. 1 μL sample solution was injected for
analysis. The SCFAs were identified by their specific
retention times under the above GC conditions. Pro-
pionic acid calibration curve was made in the range
of 0.75–6 mmol/L, and the concentration of the sam-
ple solution was converted to the propionic acid con-
centration in the colon contents.
Transepithelial electrical resistance (TER) in the colonic
wall using an Ussing chamber
Approximately 2 cm of colonic tissues were quickly
taken from the rats within 5 min after anesthetization.
Each specimen was opened along the mesenteric line
and then rinsed with ice-cold 0.9% sodium chloride solu-
tion and kept in the same solution aerated with carbo-
gen (95% O2–5% CO2) before being mounted in an
Ussing chamber. Prepared colonic specimens were
mounted on a 6-Channel EasyMount Ussing Chamber
System (Physiologic Instruments, USA) that exposed a
circular area of 0.031 cm2. Then, 5 mL of Manital-Krebs
buffer was added to the side of the mucosa while 5 mL
of Glucose-Krebs buffer was added to the serosa side.
The Ussing chamber system was maintained at a con-
stant temperature of 37 °C by using circulating water,
and the medium on both sides was filled with carbogen
(95% O2–5% CO2). Transepithelium electrical resistance
Xia et al. Lipids in Health and Disease  (2017) 16:62 Page 2 of 8
(TER) was recorded for each specimen for 120 min after
a 10 min stable period using the Ussing chamber
technique.
Western blot
After being excised and rinsed with ice-cold 0.9% so-
dium chloride solution, the proximal colons were ho-
mogenized by mechanical disruption in lysis buffer
(50 mM Tris pH 7.4, 150 mM NaCl, 1% TritonX-100,
1% sodium deoxycholate, 0.1% SDS, 2 mM sodium pyro-
phosphate, 25 mM β-glycerophosphate, 1 mM EDTA,
1 mM Na3VO4, 0.5 mg/L leupeptin, 1 mM PMSF) and
incubated on ice for 30 min. The lysates were centri-
fuged (10,000 r/min) for 30 min. The protein extracts
were used to determine the quantity of total protein with
the BCA method, and the extracts were boiled with SDS
loading buffer and separated by 10% SDS–PAGE gels.
After transferring the proteins to polyvinylidene fluoride
membranes, the blotting procedure was performed as
follows: the membranes were blocked in 5% nonfat milk
in Tris Buffered Saline with Tween-20 detergent (TBST)
for two hours at room temperature, incubated with pri-
mary antibodies (rabbit anti-Claudin-1, Claudin-8,
Occludin, p38 MAPK, phospho-p38 MAPK, ERK1/2,
phospho-ERK1/2, 1:1000 and mouse anti-GAPDH,
1:5000) overnight at 4 °C and then incubated with sec-
ondary antibodies for two hours at room temperature.
The chemiluminescent signals of the bands were col-
lected using the ChemiDoc MP system (Bio-Rad, USA).
Quantification of protein intensity was performed using
Image J software, and the results were expressed as the
ratio of relative intensity of target proteins to the in-
ternal standard, GAPDH.
Immunohistochemistry
Next, 4 μm sections were placed on clean, positively-
charged microscope slides and heated in a tissue-drying
oven for 2 h at 60 °C. The sections were washed in xy-
lene 3 times for 5 min for deparaffinization and hydrated
through a series of graded concentrations of alcohol.
The slides were heated in 10 mM sodium citrate buffer
at pH 6.0 at 100 °C for 20 min and cooled by incubation
at room temperature in buffer for 20 min for antigen re-
trieval. Endogenous peroxidase activity was blocked with
3% H2O2 for 5 min. Subsequently, sections were blocked
with BSA for 30 min and then incubated with the pri-
mary antibodies (rabbit anti-ZO-1, Claudin-8, 1:300)
overnight at 4 °C. Afterwards, the sections were incu-
bated with the biotinylated goat anti-rabbit IgG polymer
for 20 min at room temperature. Immunoreactivity was
visualized by diaminobenzidine, and the sections were
counterstained with hematoxylin. Finally, the slides were
dehydrated and mounted. A microscope (BX51, OLYM-
PUS, Japan) was used to examine the specimens.
Statistical analysis
Statistical analyses were conducted using SPSS Statistics
23.0 (IBM Corporation, USA) and Prism 7.0 (GraphPad
Software, Inc. USA) for Mac OS X. All of the data are
shown as the means ± standard deviation (SD). Data on
the TER were analyzed using a repeated measures ana-
lysis of variance (ANOVA), and the t test was used for
the comparison between the two groups. P < 0.05 re-
ferred to significant differences.
Results
Administration of propionic acid by oral gavage
enhanced the concentration in colonic contents
Figure 1a shows a typical chromatogram of a standard
mixture containing the major SCFAs (acetic acid, pro-
pionic acid and butyric acid). The standard mixture was
dissolved in ethyl acetate, and the peaks were identified
by comparing retention times after injecting a series of
graded concentrations of the individual SCFAs. To
measure the concentration of propionic acid in the co-
lonic contents, the calibration curve of propionic acid
(y = 3.8431 × + 16.915, where (x) is the concentration
(mM) and (y) is the peak area count) was performed and
showed good linearity (R2 ≥ 0.997) for a wide range of
concentrations (4–32 mM) that allowed the measure-
ment of propionic acid in the proximal colon content
samples. Figure 1b, d shows a chromatogram of SCFAs,
particularly propionic acid in the colonic content sam-
ples of the control group and the propionic acid group.
The difference of the concentration of propionic acid in
the colonic contents between the oral administration of
the normal saline solution and propionic acid by gavage is
shown in Fig. 1c. The concentration of propionic acid in
the control group (18.1 ± 0.9 mmol/kg) and the propionic
acid group (23.5 ± 1.9 mmol/kg) was measured by the GC
method, as previously described, and both concentrations
were in the range of the physiological concentration in the
proximal colon[16]. The propionic acid content in the
proximal colon after the rats were given an oral 2 mL/10 g
of 200 mM propionic acid solution by gavage twice a day
was significantly higher than the control group (P < 0.05).
Higher concentration of propionic acid enhanced
intestinal epithelial barrier function
TER was detected by the Ussing chamber system, which is a
representation of intestinal epithelial barrier function [17],
and a trend of slowing down for both the control and pro-
pionic acid groups over the 120 min incubation time in vitro
was found. However, the TER was significantly higher after
the rats received 200 mM propionic acid by oral gavage
twice a day for ten days compared to treatment with normal
saline solution at all time points, particularly the initial value
at 0 min (propionic acid group: 86.2 ± 11.6 Ω.cm2, control
group: 69.4 ± 10.5Ω.cm2), as shown in Fig. 2 (P < 0.05).
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A higher concentration of propionic acid enhanced the
intestinal barrier by increasing the expression of Claudin-1,
Claudin-8 and Occludin
Transmembrane elements, such as occludin and claudin,
as well as the peripheral membrane protein ZO-1, are
major components of the TJ. A ~22 kDa band for
Claudin-1, ~30 kDa for Claudin-8 and ~59 kDa for
Occludin appeared in the Western blot analyses and
demonstrated changes in expression after the oral ad-
ministration of 200 mM propionic acid compared to the
control group. Figure 3a shows the signal bands of pro-
teins detected at the expected molecular weights. The
results of the proteins expression were summarized as a
ratio of relative intensity of the target proteins to
GAPDH, as shown in Fig. 3b, c, d. The expression of
Claudin-1, Claudin-8 and Occludin in the proximal
colon increased significantly compared to the control
group (P < 0.05).
ZO-1 and Occludin staining in proximal colon epithelia
Immunohistochemistry was performed to analyze the
expression and distribution of TJs in the proximal colon
by staining for the ZO-1 and Claudin-8 proteins. As
Fig. 4 shows, ZO-1 and Claudin-8 were located at the
superficial layer of the colonal mucosa connecting the
epithelia and were consistent with TJ distribution. The
staining intensity of ZO-1 and Claudin-8 in the propio-
nic acid group (Fig. 4c, d) was significantly higher for
both proteins compared to the control group (Fig. 4a, b)
(P < 0.05), which agreed with the results of the Western
blots. In addition, the enhancement of Claudin-8 expres-
sion was more obvious compared to that of ZO-1.
Propionic acid enhanced the intestinal barrier via
phosphorylation of ERK1/2 and p38 MAPK
We measured the changes in phosphorylation status of
ERK1/2 (~44/42KD) and p38 (~43KD) after the oral
Fig. 2 Transepithelial electrical resistance (TER) of proximal colonic
specimens of propionic acid and the control group in vitro detected
with Ussing chambers over a 120 min incubation time. Each value
was presented as the mean ± SD (n = 9), and significant differences
between groups are indicated as *P < 0.05 according to the results
of a repeated measures analysis of variance (ANOVA)
Fig. 1 Gas chromatograms of standard mixtures (a) and proximal colon contents of the control group and propionic acid group (b, d). Peak
identification: 1: acetic acid; 2: propionic acid; 3: butyric acid. Concentration of propionic acid (mmol/kg) in the proximal colon contents for ten
days of oral gavage with a normal saline solution or 200 mM propionic acid in Sprague-Dawley rats (c). Each value was presented as the mean ±
SD (n = 8), and significant differences between the groups are indicated as *P < 0.05 according to the results of a t-test
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administration of 200 mM propionic acid. Figure 5a, b
shows the signal bands of proteins detected at the ex-
pected molecular weights and the expression levels of
phosphorylated ERK1/2, p38 MAPK were significantly
increased in the propionic acid group compared to the
control group (P < 0.05).
Discussion
During lactation, individuals are susceptible to intestinal
diseases, such as necrotizing enterocolitis, because the
intestinal mucosal barrier has not yet matured and there
is a lack of resistance to various stressors [14]. There-
fore, pre-weaning male Sprague-Dawley rats 7 days after
birth, which simulated the neonatal period in humans,
were used as models in our research. Their proximal co-
lonic contents were extracted, and we determined the
amount of propionic acid in the contents after the con-
tinuous oral administration of 200 mM propionic acid
for ten days. The results of the GC analysis revealed that
the propionic acid group had a greater propionic acid
concentration in the proximal colon compared to the
control group. Therefore, we discovered that the oral
Fig. 3 Western blots of Occludin, Claudin-8 and Claudin-1 in the proximal colon and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
performed as an internal standard (a). The relative density analysis of the control and propionic acid groups was summarized as the ratio of
the relative intensity of target proteins to GAPDH (b, c, d). Each value was expressed as the mean ± SD (n = 10), and significant differences between
the groups are indicated as *P < 0.05 according to the results of a t-test
Fig. 4 Two of the major tight junction proteins, ZO-1 and Claudin-8, were stained different grades of brown by immunohistochemistry (X 400). The
brown staining of the proximal colonic epithelia lining villi in the propionic acid group (c, d) was greater compared to the control group (a, b)
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administration of 0.2 mL/10 g of 200 mM propionic acid
by gavage increased the propionic acid concentration
even though a majority of the propionic acid was
absorbed by the small intestine [18].
In the physical environment, the primary amount of
propionic acid was derived from the fermentation of un-
digested food by the colonic microbiota. Propionic acid
has various functions in the colon as a major player in the
maintenance of gut and immune homeostasis [19, 20].
The physiological concentration of propionic acid could
immediately enhance barrier function of the colonic epi-
thelium over a short period of time in vitro [21, 22]. As far
as we know, studies of the long-term promotion effect of
propionic acid in the colon in vivo, particularly for pre-
weaning rats, are limited. To maintain the intact structure
of the proximal colon epithelium [21], we detected the
TER of whole colonic tissues with an Ussing chamber.
The results showed that a higher concentration of propio-
nic acid could promote proximal colonic barrier function
in vivo, which was supported by greater TER values. The
TJ is the most important structure in the mucosal barrier,
and it plays a critical role in the maintenance of mucosal
barrier function [23]. We assumed that a higher concen-
tration of propionic acid may influence the expression of
ZO-1, Claudin-8, Claudin-1 and Occludin, which are the
major components of the TJ. The results of the Western
blots demonstrated that the expression levels of Claudin-
1, Claudin-8 and Occludin increased after the oral admin-
istration of 200 mM propionic acid for ten days; moreover,
the immunohistochemistry of ZO-1 and Claudin-8 was
consistent with the Western blot results.
Numerous studies have shown that under pathological
conditions, such as inflammatory bowel disease and
obesity, the increase in gut permeability is associated
with much lower concentrations of SCFAs in the intes-
tine [2, 24]. Oral supplementation of SCFAs after
intestinal damage can suppress colonic epithelial perme-
ability [25–27]. Furthermore, under physiologic status,
the long-term promotive effect of a higher concentration
of propionic acid on proximal colonic barrier function of
pre-weaning rats was confirmed in our study.
Several molecular mechanisms by which SCFAs to
modulate biological responses of the host have been
proposed and elucidated. The major mechanisms in-
volves the direct inhibition of histone deacetylases
(HDACs) to directly regulate gene expression [28–30]
and signaling through G-protein-coupled receptors
(GPCRs) [31–33]. Propionic acid was the most potent
and efficacious ligand for GPCR4 [34]. In this study,
we showed that phosphorylated ERK1/2 and p38
MAPK were more strongly expressed in colonal mu-
cosa after the oral administration of 200 mM propio-
nic acid during lactation compared to the control
group. As an intracellular mechanism, the ERK1/2 or
p38 MAPK pathways is acknowledged as one of sig-
nals downstream of GPCRs [35–37]. It was previously
reported that the ERK1/2 and p38 pathways are in-
volved in the regulation of cell proliferation [38].
Therefore, our study suggested that ERK1/2 and p38
MAPK signaling pathways were involved in the pro-
pionic acid related promotion effect on colonic bar-
rier function. But, the mechanism underlying the
propionic acid activation of ERK1/2 and p38 MAPK
remains to be further elucidated.
Conclusions
We concluded that continuous oral administration of
propionic acid during lactation may increase its con-
centration in the proximal colon and promote epithe-
lial barrier function of proximal colon by enhancing
the expression of ZO-1, Claudin-8, Claudin-1 and
Occludin via increases in the expression of ERK1/2
Fig. 5 The expression of ERK1/2 and phospho-ERK1/2 (a), p38 MAPK and phospho-p38 MAPK (b) in the proximal colon and the phosphorylation status
of ERK1/2 and p38 were summarized as the ratio of the relative intensity of P-ERK1/2 to ERK1/2 and P-p38 to p38, respectively. Each value was
expressed as the mean ± SD (n = 10), and significant differences between the groups are indicated as *P < 0.05 according to the results of a t-test
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and p38 MAPK. Our results also highlighted the po-
tential value of propionic acid for the prevention and
treatment of intestinal diseases, such as necrotizing
enterocolitis, and the regulation of nutrition in
newborns.
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